<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Immunity and Infection</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3DAD3B08-2959-4441-9FB0-45C893EE371B"><gtr:id>3DAD3B08-2959-4441-9FB0-45C893EE371B</gtr:id><gtr:firstName>B</gtr:firstName><gtr:surname>Stephenson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ011509%2F1"><gtr:id>EDBAC9F3-A8B8-4DC6-953A-1D6A200539B3</gtr:id><gtr:title>The Functional Significance of the Fn14/TWEAK Receptor-Ligand System in Ductular Reactive Cell Differentiation and Bile Ductule Neogenesis.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/J011509/1</gtr:grantReference><gtr:abstractText>Liver disease is now a significant health problem in the UK. It accounts for increasing ill-health in the community, hospital admissions and death rates. It also contributes to increasingly higher healthcare costs to the National Health Service. Diseases involving the bile ducts within the liver have also increased dramatically. These diseases include primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and organ rejection after liver transplantation. It is also observed in livers donated for transplantation after cardiac death, a source of organs on which the NHS Transplant service is becoming more reliant.

Normally the bile ducts drain bile from the liver to the gut to help with digestion. Diseased bile ducts are progressively destroyed, termed ductopenia. The liver has a tremendous capacity to regenerate and make new bile ducts. However, eventually ductopenia from overwhelming destruction of the bile ducts causes an accumulation of bile in the liver and leads to end-stage liver disease. At that point the main treatment is a liver transplant which itself is associated with potentially life-threatening complications. Because the number of organs available for transplantation currently does not meet demand, there is an urgent need to understand the mechanisms which regulate ductopenia and bile duct regeneration.

Precursor cells near the bile ducts, termed ductular reactive cells, promote regeneration of the bile ducts. A molecule called Fn14 is found on these ductular reactive cells. The corresponding molecule to Fn14 called TWEAK is found on certain white blood cells near diseased bile ducts. The interaction of Fn14 and TWEAK might play a crucial role in bile duct regeneration. I propose to study the effects of Fn14 and TWEAK on the bile ducts and the ductular reactive cells in the Centre for Liver Research at the University of Birmingham. This will primarily use bile ducts and ductular reactive cells that have been isolated from diseased livers from the liver transplant programme at the Queen Elizabeth Hospital in Birmingham and obtained with patients' permission. I will initially investigate how much Fn14 is present on the bile ducts and ductular reactive cells in these livers. Additionally I will study what happens to the bile ducts and the ductular reactive cells when the Fn14 and TWEAK molecules interact. Further investigation will focus on if and how the Fn14 molecule influences the ductular reactive cells become regenerating and functioning bile ducts.

Overall this research will enable a better understanding of bile duct regeneration and potentially lead to the development of treatments for ductopenia to ultimately help prevent patients needing a liver transplant.</gtr:abstractText><gtr:technicalSummary>The novel TNF receptor Fn14 is highly expressed on cholangiocytes in areas of ductular regeneration in the inflammed liver. This project will characterise the role of Fn14 and its ligand TWEAK in remodelling and differentiating intrahepatic bile ducts by cholangiocytes and their ductular reactive cell precursors. This will determine the Fn14/TWEAK system as a potential therapeutic target for chronic ductopenic liver diseases.

Fundamental aims are to define:
1.Fn14/TWEAK expression in normal and ductopenic livers.
2.The functional role of Fn14/TWEAK in biliary remodelling by mature cholangiocytes.
3.The phenotype of ductular reactive cells allowing isolation and culturing of cholangiocyte precursors.
4.The role of Fn14/TWEAK in ductular reactive cell differentiation forming functional biliary architecture.

Project design:
(1)Human studies: cholangiocytes will be isolated from explanted livers. Detailed analysis of Fn14/TWEAK expression and functional outcome of Fn14/TWEAK interaction will utilise multicolour confocal microscopy, flow cytometry and cell IQ for cholangiocyte migration.
(2)Isolation of human ductular reactive cells: by antibody phenotyping before positive and negative fluorescent cell-sorting.
(3)Murine studies: to determine the effects of Fn14/TWEAK using wildtype and Fn14 knockout specimens in liver injury models including carbon tetrachloride fibrosis, bile duct ligation cholestasis and partial hepatectomy.</gtr:technicalSummary><gtr:potentialImpactText>This project contains a number of novel scientific aspects as previously outlined. Therefore the immediate economic and societal impact is likely to be limited. Nevertheless it is important to plan for the longer term benefits of this research.

This research will firstly emphasise the importance of medical staff to investigating the Fn14/TWEAK receptor-ligand system in hepatic inflammation and repair and their significant contribution towards consent and acquisition of human tissue by surgeons as well as the processing of samples by pathologists. Not only does this have workforce planning implications if an increased number of human samples are processed from other centres, but with appropriate engagement with trainee doctors also encourage more of them to take time out-of-programme from their respective Deaneries to undertake research, ideally at the NIHR Biomedical Research Unit and Centre for Liver Research. This would have workspace implications within the laboratory due to the increasing demand of researchers actively wanting to join the laboratory. It could promote expanding our research facilities at the University of Birmingham.

If it can be demonstrated that the Fn14/TWEAK receptor-ligand system is an appropriate therapeutic target then the commercialisation then this would, in conjunction with our collaborators at Biogen Idec Inc., lead to the creation of spin-off companies in the UK. The University of Birmingham can specifically deal with intellectual property issues relating to commercialisation. Such companies could promote investment into the research and development facilities within or near to our research establishment, contributing to our local economy and the creation of jobs. These are longer term impacts.

Further long term impacts revolve around the need for rigorous clinical trials to ascertain the population effects of this novel therapy. The appropriate clinicians would need to be aware of these ongoing trials. If successful then this may influence provision of NHS services which currently can be time and cost demanding. It may obviate the need for invasive radiological procedures required to stent biliary strictures, prevent biliary reconstructive surgery or possibly orthotopic liver transplantation thus improving the morbidity and mortality of patients. The investment in a therapeutic target for Fn14/TWEAK would be offset by the significant reduction in costs from current treatment options.

Throughout this project there would need to be significant public engagement to ensure that they are aware of firstly the impact of cholangiopathies on morbidity and mortality from chronic liver disease and secondly that research that could have a significant impact on public health is being conducted.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>209020</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>British Science Festival - Your Astonishing Liver, A Transplant Revolution being Trialled in Birmingham.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D461ABCB-1B8F-4FA9-9762-AA58D3616327</gtr:id><gtr:impact>Many questions on the potential uses of Normothermic Machine Liver Perfusion in liver transplantation by members of the public.

Other researchers present at the meeting wanting to meet to discuss potential collaborations.</gtr:impact><gtr:outcomeId>54614518332506.63254918</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.britishscienceassociation.org/british-science-festival/your-astonishing-liver</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Normothermic Machine Liver Perfusion on NIHR BRU and Centre for Liver Research Stand at Queen Elizabeth Hospital Research Showcase Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AFF18653-91CA-4C1F-8C7B-82247BF8A371</gtr:id><gtr:impact>Interesting questions by members of the public and by clinicians on how Normothermic Machine Liver Perfusion could be used in liver transplantation and research.

During the event, students asked if they could visit the laboratory and see the Normothermic Liver Perfusion Machine in action.</gtr:impact><gtr:outcomeId>5461480c84ce28.95770302</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.birminghamyearofscience2014.com/event/research-showcase-2014/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>QEHB Charities</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Queen Elizabeth Hospital Birmingham Charity (QEHB)</gtr:fundingOrg><gtr:id>3D0AAFDB-C403-4449-AEB3-6695E76A1F87</gtr:id><gtr:outcomeId>54614334677b73.68237803</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4961</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>College Research Development Fund - Preliminary Data Award</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>University of Birmingham</gtr:fundingOrg><gtr:id>BBFBDD31-BBA4-4047-B6CF-5F1DFF390A16</gtr:id><gtr:outcomeId>546142b5ddffd7.22603336</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4998</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>College Research Development Fund - Preliminary Data Award</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>University of Birmingham</gtr:fundingOrg><gtr:id>501DD065-C4EF-4DEE-94BA-6AA8E4A7B043</gtr:id><gtr:outcomeId>qGaq4MJ7NUJ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>College Research Development Fund - Travel Award</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>University of Birmingham</gtr:fundingOrg><gtr:id>0488E292-F784-4E0D-85F9-9EF8F05931C5</gtr:id><gtr:outcomeId>jkgXyh5e8Gh</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Deaths from liver disease have soared by 40 per cent in a decade and continue to rise. Liver transplantation is a highly successful treatment of end stage liver disease, fulminant hepatic failure and early stage primary liver cancer. The demand for donor livers for transplantation greatly exceeds supply and approximately 20% of patients die whilst awaiting transplantation. Normothermic machine liver perfusion (NMLP) is a novel technique developed for the purposes of organ preservation, which we have also found allows monitoring of liver graft function ex-vivo by measuring bile production, whilst permitting objective assessment of liver biochemistry and blood flow. The OrganOx metra, the NMLP device we are using, is CE marked but is not currently licensed for this particular use and the livers will not be transported using this device (which the CE mark currently covers). The device will be used at a particular site (in this case University Hospitals Birmingham) and after a period of static cold storage during which the liver will be transported to the hospital for testing on the device. The study population will be extended criteria donor livers, rejected for transplantation by all UK centres, which are then found to be functioning during perfusion and transplanted into &amp;quot;medium to low-risk&amp;quot; liver transplant recipients. VITTAL is an open label, non-randomised, prospective, single arm, 2-part trial the objectives of which are to:

Further validate liver viability assessment criteria
Perform the phase 2 study transplanting successfully resuscitated &amp;quot;rejected&amp;quot; livers
Establish the feasibility of NMLP as a means to increase the number of transplantable livers.
Identify novel biomarkers that are indicative of liver quality and function In terms of intervention, the procurement and transplantation of the organs will follow the current standard of care. The only deviation from the current standard will be the normothermic perfusion of organs following static cold storage in order to test their ability to function. This study is based on results from a 5-case pilot series which transplanted low-risk recipients with organs that had been rejected for transplantation but had been shown to function on the normothermic machine perfusion device. This work is currently in the process of being published. The main risk would be the transplantation of a non-functioning graft (resulting in a case of primary non-function that could result in re-transplantation or patient death.) Based on our pre-clinical research and clinical pilot series we believe the criteria we have identified that indicate organ function are stringent and significantly reduce this risk.

Funders: Wellcome Trust</gtr:description><gtr:id>88963C64-6CD3-46B2-B43A-5D0DF00CAA88</gtr:id><gtr:impact>First human liver transplantation using a marginal allograft resuscitated by normothermic machine perfusion.
Perera T, Mergental H, Stephenson B, Roll GR, Cilliers H, Liang R, Angelico R, Hubscher S, Neil DA, Reynolds G, Isaac J, Adams DA, Afford S, Mirza DF, Muiesan P.
Liver Transpl. 2016 Jan;22(1):120-4. doi: 10.1002/lt.24369.

Transplantation of Declined Liver Allografts Following Normothermic Ex-Situ Evaluation.
Mergental H, Perera MT, Laing RW, Muiesan P, Isaac JR, Smith A, Stephenson BT, Cilliers H, Neil DA, H&amp;uuml;bscher SG, Afford SC, Mirza DF.
Am J Transplant. 2016 Nov;16(11):3235-3245. doi: 10.1111/ajt.13875.</gtr:impact><gtr:outcomeId>58ca316f7a50e8.08631318</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Normothermic machine liver perfusion of discarded human livers</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Using normothermic machine perfusion of human livers discarded from the NHSBT Transplantation programme to study liver physiology, to test novel therapeutics and resuscitate/recondition such livers with the prospect of transplantation.</gtr:description><gtr:id>BDBFEB50-80A5-48EF-8D2E-3520CD74B9BC</gtr:id><gtr:impact>Preimplant Normothermic Liver Perfusion of a Suboptimal Liver Donated After Circulatory Death.</gtr:impact><gtr:outcomeId>58ca2ec7490250.34964377</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Normothermic machine liver perfusion as a research tool</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7DDBD619-1708-4055-8E59-2A6210D4CB9E</gtr:id><gtr:title>310 FGF INDUCIBLE PROTEIN 14 IS UPREGULATED IN NEOVESSELS DURING CHRONIC INFLAMMATORY LIVER DISEASE AND PROMOTES INTRAHEPATIC ENDOTHELIAL CELL ANGIOGENESIS IN VITRO FOLLOWING STIMULATION VIA TWEAK</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f26b7b85efc7e9717a2f4996b822b5f1"><gtr:id>f26b7b85efc7e9717a2f4996b822b5f1</gtr:id><gtr:otherNames>Munir M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>ehLzZFzbyhU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9983FE2A-1326-47AA-871E-DCA85EF8C5A0</gtr:id><gtr:title>Normothermic machine liver perfusion: a tool to assess the viability of human donor livers.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed926148319a4f310de57c699273d3f7"><gtr:id>ed926148319a4f310de57c699273d3f7</gtr:id><gtr:otherNames>Stephenson BTF</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>56e15354671274.23685904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2018C0BA-4AE1-4207-91A6-79A5BBF2D402</gtr:id><gtr:title>Fn14 is expressed on neoplastic cholangiocytes in intrahepatic cholangiocarcinoma and promotes necrosis after interaction with TWEAK</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3944bab48f6c99fe7b2cf4c1afb8ce2"><gtr:id>f3944bab48f6c99fe7b2cf4c1afb8ce2</gtr:id><gtr:otherNames>Stephenson B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_15488_13_60544_9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA2CE044-4B5F-4AEC-BB46-4F0BEFA49719</gtr:id><gtr:title>First human liver transplantation using a marginal allograft resuscitated by normothermic machine perfusion.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d451b186c824cafa5e8d64184c6ac07"><gtr:id>4d451b186c824cafa5e8d64184c6ac07</gtr:id><gtr:otherNames>Perera T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>56e14d23413614.06808254</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95382679-2977-43D8-B9FB-8F8F3BA99B8A</gtr:id><gtr:title>698 FN14 IS EXPRESSED ON NEOPLASTIC CHOLANGIOCYTES IN INTRA-HEPATIC CHOLANGIOCARCINOMA AND PROMOTES NECROSIS AFTER INTERACTION WITH TWEAK</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3944bab48f6c99fe7b2cf4c1afb8ce2"><gtr:id>f3944bab48f6c99fe7b2cf4c1afb8ce2</gtr:id><gtr:otherNames>Stephenson B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>SzXA3W2mCBA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F8AC82F-7075-4D6C-9617-9B5B01F55927</gtr:id><gtr:title>The Use of an Acellular Oxygen Carrier in a Human Liver Model of Normothermic Machine Perfusion.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c95e5e83ac44e98a09f80b0c315afe1"><gtr:id>3c95e5e83ac44e98a09f80b0c315afe1</gtr:id><gtr:otherNames>Laing RW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>5aaa837ac81a75.43361480</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18A6D8FC-5AF9-44F8-93B0-584A3749CE4A</gtr:id><gtr:title>Normothermic machine liver perfusion in the ex-vivo assessment of discarded human donor livers.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed926148319a4f310de57c699273d3f7"><gtr:id>ed926148319a4f310de57c699273d3f7</gtr:id><gtr:otherNames>Stephenson BTF</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>56e15546d6dc08.57522923</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FA067EA-E6A7-48FB-8582-7B25DF81EB98</gtr:id><gtr:title>1138 THE FN14/TWEAK RECEPTOR-LIGAND SYSTEM REGULATES HEPATIC STELLATE CELL FUNCTION IN LIVER FIBROSIS</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67e000b9b63dbeb08f7036e69e9d1799"><gtr:id>67e000b9b63dbeb08f7036e69e9d1799</gtr:id><gtr:otherNames>Wilhelm A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>WQtHjT3e23u</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6309694-F4CE-4C5C-884C-D09FCCD25958</gtr:id><gtr:title>PMO-131 FGF inducible protein 14 is upregulated in neovessels during chronic inflammatory liver disease and promotes intrahepatic endothelial cell angiogenesis in vitro following stimulation via tweak</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f26b7b85efc7e9717a2f4996b822b5f1"><gtr:id>f26b7b85efc7e9717a2f4996b822b5f1</gtr:id><gtr:otherNames>Munir M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>HPXNMNWABGg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E8C2E02-53FD-4E5A-8E25-21B01969D6B6</gtr:id><gtr:title>Transplantation of Declined Liver Allografts Following Normothermic Ex-Situ Evaluation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94584ef4f4b809343feb5ca48f389c7e"><gtr:id>94584ef4f4b809343feb5ca48f389c7e</gtr:id><gtr:otherNames>Mergental H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>58ca2ba3e931c4.23532075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62F8FA5C-4DE1-41F4-8429-35918A3A4F77</gtr:id><gtr:title>Quantitative assessment of the cell surface proteome to identify novel therapeutic targets in cholangiocarcinoma.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3944bab48f6c99fe7b2cf4c1afb8ce2"><gtr:id>f3944bab48f6c99fe7b2cf4c1afb8ce2</gtr:id><gtr:otherNames>Stephenson B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56e14f72dddfa0.23925121</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>979418BF-D264-4BB0-AF41-53D984EA68A7</gtr:id><gtr:title>Reticulocyte count and hemoglobin concentration predict survival in candidates for liver transplantation.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>54614ba7b9fe14.76572969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8A51302-E935-4490-8E70-DD100F6FC352</gtr:id><gtr:title>PMO-113 FN14 is expressed on cholangiocytes and promotes biliary ductular remodelling via apoptosis and reactive oxygen species after interaction with tweak</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3944bab48f6c99fe7b2cf4c1afb8ce2"><gtr:id>f3944bab48f6c99fe7b2cf4c1afb8ce2</gtr:id><gtr:otherNames>Stephenson B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>Vjf89rmPUpS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65908D8C-896D-46B8-A15C-537BFEA92317</gtr:id><gtr:title>Transplantation of a discarded human liver reconditioned using Normothermic Machine Liver Perfusion - A Case Report.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed926148319a4f310de57c699273d3f7"><gtr:id>ed926148319a4f310de57c699273d3f7</gtr:id><gtr:otherNames>Stephenson BTF</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>56e1546da4f468.44907036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCFF034F-BAC4-4066-904A-1293B2ADC2BB</gtr:id><gtr:title>Normothermic machine liver perfusion: a tool to assess the viability of human donor livers.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed926148319a4f310de57c699273d3f7"><gtr:id>ed926148319a4f310de57c699273d3f7</gtr:id><gtr:otherNames>Stephenson BTF</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>56e1521312bd75.15357609</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88066B7B-1A30-4685-A328-E371C9F9D1A1</gtr:id><gtr:title>Lipid metabolism and functional assessment of steatotic discarded human livers undergoing 24 hours normothermic machine perfusion.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/364698a6c84fcd71d45f587d5c89f915"><gtr:id>364698a6c84fcd71d45f587d5c89f915</gtr:id><gtr:otherNames>Boteon YL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>5aaa837a949800.36590208</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J011509/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>